Viewing Study NCT02225093

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:24 AM
Ignite Modification Date: 2026-02-24 @ 5:02 PM
Study NCT ID: NCT02225093
Status: COMPLETED
Last Update Posted: 2017-06-27
First Post: 2014-08-22
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer
Sponsor: Astellas Pharma Europe B.V.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pharmacokinetics of Dextromethorphan View
None Pharmacokinetics of Caffeine View
None Prostate Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Safety View
None Dextromethorphan View
None CYP2D6 View
None Phase 1 View
None Prostate cancer View
None CYP1A2 View
None Pharmacokinetics View
None Drug-drug interactions View
None Caffeine View
None Enzalutamide View